Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of fenebrutinib in refractory chronic spontaneous urticaria
2016-004624-35Phase 2Terminated
- Sponsor
- Genentech
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing fenebrutinib with placebo (2 arms). Primary endpoint: Change from baseline in UAS7 at Day 57 (Week 8). Started Feb 2017; status: terminated.
02
Drugs
fenebrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2016-004624-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004624-35.